Biogen (BIIB) Short-term Investments (2009 - 2026)

Biogen (BIIB) has reported Short-term Investments for 17 consecutive years, with $900.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Short-term Investments changed N/A year-over-year to $900.0 million; the TTM figure through Mar 2026 stood at $900.0 million (changed N/A YoY), while the FY2025 annual figure was $807.2 million, changed N/A from the prior year.
• Short-term Investments came in at $900.0 million for Q1 2026 at Biogen, up from $807.2 million in the prior quarter.
• The five-year high for Short-term Investments was $3.5 billion in Q2 2023, with the low at $97.6 million in Q3 2025.
• Average Short-term Investments over 4 years is $1.6 billion, with a median of $1.5 billion recorded in 2022.
• The largest YoY upside for Short-term Investments was 64.37% in 2022 against a maximum downside of 12.58% in 2022.
• Year by year, Short-term Investments stood at $1.5 billion in 2022, then surged by 134.85% to $3.5 billion in 2023, then sank by 76.67% to $807.2 million in 2025, then rose by 11.5% to $900.0 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $900.0 million, $807.2 million, and $97.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.